The second meta-analysis included randomized controlled trials (ELIXA, HARMONY OUTCOMES, PIONEER-6, SUSTAIN-6, LEADER) that compared GLP-1 RAs with placebo and met the critical criterion of a proportion of patients with T2DM and MI > 30% (79). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.